- Home
- SEE vs ACAD Comparison
SEE vs ACAD Comparison
Compare SEE & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEE | ACAD |
|---|---|---|
| Founded | 1960 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.4B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | SEE | ACAD |
|---|---|---|
| Price | $41.95 | $21.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 22 |
| Target Price | ★ $43.50 | $29.95 |
| AVG Volume (30 Days) | ★ 2.7M | 1.3M |
| Earning Date | 03-02-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | 13.73 | ★ 98.53 |
| EPS | ★ 3.09 | 1.54 |
| Revenue | ★ $5,331,600,000.00 | $1,047,118,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | $1.16 | $11.24 |
| P/E Ratio | ★ $13.55 | $14.58 |
| Revenue Growth | N/A | ★ 12.69 |
| 52 Week Low | $22.78 | $13.40 |
| 52 Week High | $44.27 | $28.35 |
Technical Indicators
Market Signals| Indicator | SEE | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 61.89 | 25.70 |
| Support Level | $41.75 | $23.37 |
| Resistance Level | $41.91 | $26.23 |
| Average True Range (ATR) | 0.10 | 0.95 |
| MACD | -0.02 | -0.41 |
| Stochastic Oscillator | 78.00 | 0.37 |
Price Performance
Historical ComparisonAbout SEE Sealed Air Corporation
Sealed Air is organized via two reporting segments. Food includes food packaging products like Cryovac, Darfresh, and OptiDure aimed primarily at meats. Protective includes Sealed Air's Bubble Wrap, Instapak, Jiffy mailers, and shrink film packaging systems that cater to industrial and e-commerce applications.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.